Drug
Cv09070101 Mrna Vaccine 50 G
Cv09070101 Mrna Vaccine 50 G: highest development phase Phase 1, developed by CureVac. 1 trial record tracked on RxWires.
- Highest phase
- Phase 1
- Developer
- CureVac
Trials
| Drug | Phase | Indication |
|---|---|---|
| CV09070101 mRNA vaccine (CVHNLC) 50 µg NCT07073183 | Phase 1 | Squamous NSCLC |
Latest
No recent events.
Follow Cv09070101 Mrna Vaccine 50 G on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.